A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Inclusion Criteria

• •Have a clinical diagnosis of type 1 diabetes for at least 1 year prior to screening
• •Have received treatment with basal-bolus insulin analog multiple daily injection therapy according to the local product label for at least 90 days prior to screening
• •Have an HbA1c value of 7.0% to 10.0%, inclusive, as determined by the central laboratory at screening.
• •Have a body mass index of ≤35 kilogram/square meter (kg/m²)